Novo CEO says obesity market won't be winner-take-all battle with Lilly
By Michael Erman NEW YORK, Aug 13 (Reuters) - Novo Nordisk CEO Mike Doustdar said investors are underestimating the demand for differentiation among obesity drugs, and that new treatment options like pills will keep it from becoming a winner-take-all battle with rival Eli Lilly. 
